NCT04546009进行中（未招募）3 期
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 992
- 试验地点
- 375
- 主要终点
- Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1
研究概览
简要总结
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For women who are premenopausal or perimenopausal and for men: treatment with approved LHRH agonist therapy for the duration of study treatment
- •Locally advanced (recurrent or progressed) or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
- •Documented ER-positive tumor and HER2-negative tumor, assessed locally
- •Patients who have bilateral breast cancers which are both ER-positive and HER2-negative can be included in the study because the metastases are suitably targeted by the study treatments. If patients have bilateral tumors which are of different biomarker status, then proof of the ER and HER2 status of the metastases is required for study entry
- •No history of systemic anti-cancer therapy for locally advanced (recurrent or progressed) or metastatic disease
- •Disease recurrence from early-stage breast cancer after standard adjuvant endocrine therapy meeting the protocol-defined criteria of having received at least 24 months of treatment without disease progression during treatment and a disease-free interval since the completion of treatment that was greater than 12 months
- •Measurable disease as defined per RECIST v.1.1 or bone only disease which must have at least one predominantly lytic bone lesion confirmed by CT or MRI which can be followed
- •Eastern Cooperative Oncology Group Performance Status 0-1
- •Adequate organ function
排除标准
- •Disease recurrence during or within 12 months of completing prior neoadjuvant or adjuvant treatment with any CDK4/6 inhibitor
- •Prior treatment with a selective estrogen receptor degrader (SERD)
- •Treatment with any investigational therapy within 28 days prior to study treatment
- •Treatment with strong CYP3A inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
- •Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
- •Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease
- •Active cardiac disease or history of cardiac dysfunction, as defined in the protocol
- •Pregnant or breastfeeding
研究组 & 干预措施
Giredestrant + Letrozole-matched Placebo + Palbociclib
Experimental
干预措施: Palbociclib (Drug)
Letrozole + Giredestrant-matched Placebo + Palbociclib
Active Comparator
干预措施: Palbociclib (Drug)
Giredestrant + Letrozole-matched Placebo + Palbociclib
Experimental
干预措施: Letrozole-matched Placebo (Drug)
Letrozole + Giredestrant-matched Placebo + Palbociclib
Active Comparator
干预措施: Giredestrant-matched Placebo (Drug)
Letrozole + Giredestrant-matched Placebo + Palbociclib
Active Comparator
干预措施: LHRH Agonist (Drug)
Giredestrant + Letrozole-matched Placebo + Palbociclib
Experimental
干预措施: Giredestrant (Drug)
Giredestrant + Letrozole-matched Placebo + Palbociclib
Experimental
干预措施: LHRH Agonist (Drug)
Letrozole + Giredestrant-matched Placebo + Palbociclib
Active Comparator
干预措施: Letrozole (Drug)
结局指标
主要结局
Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1
时间窗: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)
次要结局
- Overall Survival(From randomization to death from any cause (up to 78 months))
- Objective Response Rate, as Determined by the Investigator According to RECIST v1.1(From randomization until disease progression or death (up to 78 months))
- Duration of Response, as Determined by the Investigator According to RECIST v1.1(From first occurrence of documented objective response to disease progression or death from any cause, whichever occurs first (up to 78 months))
- Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1(From randomization until disease progression or death (up to 78 months))
- Time to Confirmed Deterioration in Pain Level, Defined as the Time to First Documented ≥2-Point Increase from Baseline in the 'Worst Pain' Item from the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire(From Baseline until treatment discontinuation (up to 78 months))
- Time to Confirmed Deterioration in Pain Presence and Interference, Defined as the Time to First Documented ≥10-Point Increase from Baseline in the EORTC QLQ-C30 Linearly Transformed Pain Scale Score(From Baseline until treatment discontinuation (up to 78 months))
- Time to Confirmed Deterioration in Physical Functioning, Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed Physical Functioning Scale Score(From Baseline until treatment discontinuation (up to 78 months))
- Time to Confirmed Deterioration in Role Functioning, Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed Role Functioning Scale Score(From Baseline until treatment discontinuation (up to 78 months))
- Time to Confirmed Deterioration in Global Health Status and Quality of Life (GHS/QoL), Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed GHS/QoL Scale Score(From Baseline until treatment discontinuation (up to 78 months))
- Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)(From treatment initiation until 30 days after the final dose of study treatment (up to 78 months))
- Number of Participants with Vital Sign Abnormalities Over the Course of the Study(Baseline, Days 1 and 15 of Cycles 1 and 2, and Day 1 of each cycle thereafter until treatment discontinuation (1 cycle is 28 days))
- Plasma Concentration of Giredestrant at Specified Timepoints(Days 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 8, and 16 (1 cycle is 28 days))
- Plasma Concentration of Palbociclib at Specified Timepoints(Days 1 and 15 of Cycle 1 (1 cycle is 28 days))
研究者
研究点 (375)
Loading locations...
相似试验
已完成
3 期
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate AsthmaAsthmaNCT02104674Hoffmann-La Roche313
已完成
3 期
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesIdiopathic Parkinson's DiseaseNCT02240030Acorda Therapeutics351
已完成
3 期
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant MelanomaMelanomaNCT01667419Hoffmann-La Roche498
招募中
3 期
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative ColitisModerately to Severely Active Ulcerative ColitisNCT06588855Hoffmann-La Roche350
招募中
3 期
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerNon-small Cell Lung CancerNCT05341583Betta Pharmaceuticals Co., Ltd.202